Which has stronger earnings & valuation, AZN or GSK?

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AstraZeneca £60.44B 3.49 £8.71B £664.00 20.47 GSK £32.78B 2.39 £2.50B £142.10 13.78

Is AZN or GSK more profitable?

GSK has a net margin of 17.78% compared to AstraZeneca's net margin of 17.19%. GSK's return on equity of 35.78% beat AstraZeneca's return on equity. Company Net Margins Return on Equity Return on Assets AstraZeneca 17.19% 22.41% 7.68% GSK 17.78% 35.78% 9.56%

Does the media refer more to AZN or GSK?

In the previous week, GSK had 4 more articles in the media than AstraZeneca. MarketBeat recorded 5 mentions for GSK and 1 mentions for AstraZeneca. GSK's average media sentiment score of 0.81 beat AstraZeneca's score of -0.06 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AstraZeneca 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GSK 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ITH or AZN?

AstraZeneca has higher revenue and earnings than Ithaca Energy. Ithaca Energy is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ithaca Energy £2.95B 1.26 £230.29M -£5.10 N/A AstraZeneca £60.44B 3.49 £8.71B £664.00 20.47

Do analysts recommend SOPH or AZN?

AstraZeneca has a consensus target price of £153.33, suggesting a potential upside of 12.82%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts plainly believe AstraZeneca is more favorable than Sophos Group plc (SOPH.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sophos Group plc (SOPH.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 AstraZeneca 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Do analysts prefer INDV or AZN?

AstraZeneca has a consensus target price of £153.33, indicating a potential upside of 12.82%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than Indivior. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indivior 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 AstraZeneca 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better valuation & earnings, INDV or AZN?

AstraZeneca has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indivior £1.40B 1.38 -£2.36M -£1.21 N/A AstraZeneca £60.44B 3.49 £8.71B £664.00 20.47

Is INDV or AZN more profitable?

AstraZeneca has a net margin of 17.19% compared to Indivior's net margin of 14.30%. AstraZeneca's return on equity of 22.41% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Indivior 14.30% -41.70% 2.37% AstraZeneca 17.19% 22.41% 7.68%

Does the media favor INDV or AZN?

In the previous week, Indivior and Indivior both had 1 articles in the media. Indivior's average media sentiment score of 0.75 beat AstraZeneca's score of -0.06 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AstraZeneca 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate HCM or AZN?

AstraZeneca has a consensus price target of £153.33, suggesting a potential upside of 12.82%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts clearly believe AstraZeneca is more favorable than HUTCHMED. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 AstraZeneca 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger earnings and valuation, HCM or AZN?

AstraZeneca has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED £548.51M 2.48 -£52.98M £53.00 2.98 AstraZeneca £60.44B 3.49 £8.71B £664.00 20.47

Is HCM or AZN more profitable?

HUTCHMED has a net margin of 104.77% compared to AstraZeneca's net margin of 17.19%. HUTCHMED's return on equity of 41.38% beat AstraZeneca's return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED 104.77% 41.38% -5.90% AstraZeneca 17.19% 22.41% 7.68%

AstraZeneca (AZN) Competitors

£135.91 +301.00 (+2.26%)

As of 12:43 PM Eastern

Compare

AZN vs. GSK, ITH, SOPH, INDV, and HCM

Should you buy AstraZeneca stock or one of its competitors? MarketBeat compares AstraZeneca with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AstraZeneca include GSK (GSK), Ithaca Energy (ITH), Sophos Group plc (SOPH.L) (SOPH), Indivior (INDV), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.

How does AstraZeneca compare to GSK?

AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

AstraZeneca has a beta of 0.214, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, GSK has a beta of 0.294, suggesting that its stock price is 71% less volatile than the broader market.

In the previous week, GSK had 4 more articles in the media than AstraZeneca. MarketBeat recorded 5 mentions for GSK and 1 mentions for AstraZeneca. GSK's average media sentiment score of 0.81 beat AstraZeneca's score of -0.06 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£60.44B	3.49	£8.71B	£664.00	20.47
GSK	£32.78B	2.39	£2.50B	£142.10	13.78

GSK has a net margin of 17.78% compared to AstraZeneca's net margin of 17.19%. GSK's return on equity of 35.78% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.19%	22.41%	7.68%
GSK	17.78%	35.78%	9.56%

AstraZeneca presently has a consensus target price of £153.33, suggesting a potential upside of 12.82%. GSK has a consensus target price of GBX 2,034.29, suggesting a potential upside of 3.92%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts plainly believe AstraZeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.3%. GSK pays an annual dividend of GBX 66 per share and has a dividend yield of 3.4%. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. GSK pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

67.8% of AstraZeneca shares are held by institutional investors. Comparatively, 56.9% of GSK shares are held by institutional investors. 0.2% of AstraZeneca shares are held by company insiders. Comparatively, 0.3% of GSK shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

AstraZeneca and GSK tied by winning 9 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to Ithaca Energy?

Ithaca Energy (LON:ITH) and AstraZeneca (LON:AZN) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

3.6% of Ithaca Energy shares are owned by institutional investors. Comparatively, 67.8% of AstraZeneca shares are owned by institutional investors. 0.2% of Ithaca Energy shares are owned by company insiders. Comparatively, 0.2% of AstraZeneca shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AstraZeneca has a net margin of 17.19% compared to Ithaca Energy's net margin of 7.53%. AstraZeneca's return on equity of 22.41% beat Ithaca Energy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ithaca Energy	7.53%	9.33%	0.18%
AstraZeneca	17.19%	22.41%	7.68%

AstraZeneca has higher revenue and earnings than Ithaca Energy. Ithaca Energy is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ithaca Energy	£2.95B	1.26	£230.29M	-£5.10	N/A
AstraZeneca	£60.44B	3.49	£8.71B	£664.00	20.47

Ithaca Energy presently has a consensus target price of GBX 205, indicating a potential downside of 9.21%. AstraZeneca has a consensus target price of £153.33, indicating a potential upside of 12.82%. Given AstraZeneca's higher probable upside, analysts plainly believe AstraZeneca is more favorable than Ithaca Energy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ithaca Energy	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Ithaca Energy pays an annual dividend of GBX 30.31 per share and has a dividend yield of 13.4%. AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.3%. Ithaca Energy pays out -594.3% of its earnings in the form of a dividend. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Ithaca Energy is clearly the better dividend stock, given its higher yield and lower payout ratio.

Ithaca Energy has a beta of 0.309, suggesting that its share price is 69% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.214, suggesting that its share price is 79% less volatile than the broader market.

In the previous week, AstraZeneca had 1 more articles in the media than Ithaca Energy. MarketBeat recorded 1 mentions for AstraZeneca and 0 mentions for Ithaca Energy. AstraZeneca's average media sentiment score of -0.06 beat Ithaca Energy's score of -0.55 indicating that AstraZeneca is being referred to more favorably in the news media.

Company	Overall Sentiment
Ithaca Energy	Negative
AstraZeneca	Neutral

Summary

AstraZeneca beats Ithaca Energy on 13 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to Sophos Group plc (SOPH.L)?

Sophos Group plc (SOPH.L) (LON:SOPH) and AstraZeneca (LON:AZN) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Sophos Group plc (SOPH.L) pays an annual dividend of GBX 0.04 per share. AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.3%. Sophos Group plc (SOPH.L) pays out 2.4% of its earnings in the form of a dividend. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

67.8% of AstraZeneca shares are held by institutional investors. 0.2% of AstraZeneca shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, AstraZeneca had 1 more articles in the media than Sophos Group plc (SOPH.L). MarketBeat recorded 1 mentions for AstraZeneca and 0 mentions for Sophos Group plc (SOPH.L). Sophos Group plc (SOPH.L)'s average media sentiment score of 0.00 beat AstraZeneca's score of -0.06 indicating that Sophos Group plc (SOPH.L) is being referred to more favorably in the media.

Company	Overall Sentiment
Sophos Group plc (SOPH.L)	Neutral
AstraZeneca	Neutral

AstraZeneca has higher revenue and earnings than Sophos Group plc (SOPH.L). Sophos Group plc (SOPH.L) is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sophos Group plc (SOPH.L)	£726.90M	0.00	N/A	£1.70	N/A
AstraZeneca	£60.44B	3.49	£8.71B	£664.00	20.47

AstraZeneca has a consensus target price of £153.33, suggesting a potential upside of 12.82%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts plainly believe AstraZeneca is more favorable than Sophos Group plc (SOPH.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sophos Group plc (SOPH.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

AstraZeneca has a net margin of 17.19% compared to Sophos Group plc (SOPH.L)'s net margin of 0.00%. AstraZeneca's return on equity of 22.41% beat Sophos Group plc (SOPH.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sophos Group plc (SOPH.L)	N/A	N/A	N/A
AstraZeneca	17.19%	22.41%	7.68%

Summary

AstraZeneca beats Sophos Group plc (SOPH.L) on 12 of the 15 factors compared between the two stocks.

How does AstraZeneca compare to Indivior?

Indivior (LON:INDV) and AstraZeneca (LON:AZN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.3%. Indivior pays out -1,243.7% of its earnings in the form of a dividend. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Indivior and Indivior both had 1 articles in the media. Indivior's average media sentiment score of 0.75 beat AstraZeneca's score of -0.06 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AstraZeneca	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Indivior has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.214, indicating that its share price is 79% less volatile than the broader market.

AstraZeneca has a consensus target price of £153.33, indicating a potential upside of 12.82%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

86.0% of Indivior shares are held by institutional investors. Comparatively, 67.8% of AstraZeneca shares are held by institutional investors. 3.4% of Indivior shares are held by company insiders. Comparatively, 0.2% of AstraZeneca shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AstraZeneca has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A
AstraZeneca	£60.44B	3.49	£8.71B	£664.00	20.47

AstraZeneca has a net margin of 17.19% compared to Indivior's net margin of 14.30%. AstraZeneca's return on equity of 22.41% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	14.30%	-41.70%	2.37%
AstraZeneca	17.19%	22.41%	7.68%

Summary

AstraZeneca beats Indivior on 13 of the 17 factors compared between the two stocks.

How does AstraZeneca compare to HUTCHMED?

HUTCHMED (LON:HCM) and AstraZeneca (LON:AZN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

20.4% of HUTCHMED shares are owned by institutional investors. Comparatively, 67.8% of AstraZeneca shares are owned by institutional investors. 2.8% of HUTCHMED shares are owned by insiders. Comparatively, 0.2% of AstraZeneca shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AstraZeneca has a consensus price target of £153.33, suggesting a potential upside of 12.82%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts clearly believe AstraZeneca is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

HUTCHMED has a net margin of 104.77% compared to AstraZeneca's net margin of 17.19%. HUTCHMED's return on equity of 41.38% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	104.77%	41.38%	-5.90%
AstraZeneca	17.19%	22.41%	7.68%

In the previous week, AstraZeneca had 1 more articles in the media than HUTCHMED. MarketBeat recorded 1 mentions for AstraZeneca and 0 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.00 beat AstraZeneca's score of -0.06 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Overall Sentiment
HUTCHMED	Neutral
AstraZeneca	Neutral

HUTCHMED has a beta of 0.368, suggesting that its share price is 63% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.214, suggesting that its share price is 79% less volatile than the broader market.

AstraZeneca has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	£548.51M	2.48	-£52.98M	£53.00	2.98
AstraZeneca	£60.44B	3.49	£8.71B	£664.00	20.47

Summary

AstraZeneca beats HUTCHMED on 11 of the 16 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZN vs. The Competition

Export

Metric	AstraZeneca	Drug Manufacturers Industry	Medical Sector	LON Exchange
Market Cap	£210.78B	£73.47B	£6.48B	£2.78B
Dividend Yield	1.78%	2.41%	2.68%	6.16%
P/E Ratio	20.47	25.08	24.66	365.72
Price / Sales	3.49	147.81	529.89	86,253.73
Price / Cash	38.89	16.01	27.92	27.85
Price / Book	5.17	3.53	10.84	7.93
Net Income	£8.71B	£3.18B	£3.56B	£5.89B
7 Day Performance	2.31%	-0.88%	1.71%	-0.87%
1 Month Performance	-2.34%	-2.42%	0.48%	-0.76%
1 Year Performance	30.43%	16.38%	32.98%	70.67%

AstraZeneca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZN AstraZeneca	3.3965 of 5 stars	£135.91 +2.3%	£153.33 +12.8%	+27.9%	£210.78B	£60.44B	20.47	83,500
GSK GSK	3.1559 of 5 stars	GBX 1,950 -0.4%	GBX 2,034.29 +4.3%	+34.0%	£78.20B	£32.78B	13.72	70,212	Insider Trade
ITH Ithaca Energy	0.8692 of 5 stars	GBX 233 +1.4%	GBX 205 -12.0%	+29.5%	£3.85B	£2.95B	N/A	220	High Trading Volume
SOPH Sophos Group plc (SOPH.L)	N/A	N/A	N/A	N/A	£2.99B	£726.90M	341.41	520
INDV Indivior	N/A	GBX 1,238 +1.6%	N/A	+18.2%	£1.93B	£1.40B	N/A	1,000	Positive News Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:AZN) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AstraZeneca (AZN) Competitors

AZN vs. GSK, ITH, SOPH, INDV, and HCM

How does AstraZeneca compare to GSK?

Summary

How does AstraZeneca compare to Ithaca Energy?

Summary

How does AstraZeneca compare to Sophos Group plc (SOPH.L)?

Summary

How does AstraZeneca compare to Indivior?

Summary

How does AstraZeneca compare to HUTCHMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN vs. The Competition

AstraZeneca Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AstraZeneca (AZN) Competitors

AZN vs. GSK, ITH, SOPH, INDV, and HCM

How does AstraZeneca compare to GSK?

Which has more volatility & risk, AZN or GSK?

Does the media refer more to AZN or GSK?

Which has stronger earnings & valuation, AZN or GSK?

Is AZN or GSK more profitable?

Do analysts prefer AZN or GSK?

Is AZN or GSK a better dividend stock?

Do institutionals and insiders believe in AZN or GSK?

Summary

How does AstraZeneca compare to Ithaca Energy?

Do insiders and institutionals hold more shares of ITH or AZN?

Is ITH or AZN more profitable?

Which has higher earnings and valuation, ITH or AZN?

Do analysts rate ITH or AZN?

Is ITH or AZN a better dividend stock?

Which has more risk and volatility, ITH or AZN?

Does the media prefer ITH or AZN?

Summary

How does AstraZeneca compare to Sophos Group plc (SOPH.L)?

Is SOPH or AZN a better dividend stock?

Do institutionals & insiders have more ownership in SOPH or AZN?

Does the media refer more to SOPH or AZN?

Which has stronger earnings and valuation, SOPH or AZN?

Do analysts recommend SOPH or AZN?

Is SOPH or AZN more profitable?

Summary

How does AstraZeneca compare to Indivior?

Is INDV or AZN a better dividend stock?

Does the media favor INDV or AZN?

Which has more risk and volatility, INDV or AZN?

Do analysts prefer INDV or AZN?

Do insiders & institutionals believe in INDV or AZN?

Which has better valuation & earnings, INDV or AZN?

Is INDV or AZN more profitable?

Summary

How does AstraZeneca compare to HUTCHMED?

Do institutionals and insiders have more ownership in HCM or AZN?

Do analysts rate HCM or AZN?

Is HCM or AZN more profitable?

Does the media prefer HCM or AZN?

Which has more risk and volatility, HCM or AZN?

Which has stronger earnings and valuation, HCM or AZN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN vs. The Competition

AstraZeneca Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools